Floatz logo

Epirubicin

Metastatic Bladder Giant Cell Urothelial Carcinoma

Fred Hutchinson Cancer CenterPhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Metastatic Bladder Giant Cell Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 2/3B
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2/3B
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2/3B
Quemliclustat
Fred Hutchinson Cancer Center
Phase 1/2CC

Same molecule, other indications

Epirubicin is also rated in:

Recurrent Breast CarcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Lung Non-Small Cell Squamous CarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
Advanced/Metastatic Gastroesophageal AdenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →